This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Spectros Retains Woodside Capital Partners To Explore Strategic Expansion Options

PORTOLA VALLEY, Calif., March 31, 2013 /PRNewswire/ -- Spectros announced today the retention of Woodside Capital Partners International to explore strategic options to accelerate the growth of its proprietary second-generation perfusion monitoring platform.  In 2012, revenue from T-Stat sensor sales continued to show double-digit growth.  In 2013, the OnCall remote monitoring smartphone application was introduced to allow real-time display of T-Stat data on smartphones at a distance.

"Woodside Capital will assist in refining Spectros' strategic vision, as well as initiating discussions with potential corporate partners to accelerate expansion into areas that require perfusion monitoring solutions superior to the first-generation technology offered by our competition," notes CFO John Bagnatori.  "The Company also believes that its broad patent portfolio of solid-state illumination and wireless technologies (30+ issued and 20+ pending patents) provides additional value, such as in the emerging remote patient monitoring market."

Spectros' flagship product, T-Stat®, is the first and only second-generation tissue oximeter on the market in the U.S., Europe, and Asia.  T-Stat is the Company's entry into a rapidly growing perfusion monitoring market.  Perfusion is the delivery of oxygen to the body's key organs, and is central to many medical conditions.  The perfusion monitoring market is currently about $400M/year, with 30% annual growth and expected to grow to over $2B by 2020.

T-Stat's revolutionary broadband sensor relies on a white LED to provide over 260 wavelengths of light, compared to just 2-4 wavelengths found in other devices.  Because of its unequaled accuracy and reliability, T-Stat is positioned to displace many first-generation products where a precise perfusion measurement is critical to treatment, including heart failure, plastic and vascular surgery, shock, transplant, trauma, endoscopy, and biopsy.

T-Stat competes with INVOS® by Covidien, FORE-SIGHT® by CAS Medical, and Cerox® by GE / ORNIM.  In wound care and reconstructive surgery, T-Stat also competes with T.Ox® by ViOptix, SPY® by Novadaq, and flow monitoring devices by Moore Instruments.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs